Hear about the latest developments in research and treatment of interstitial lung diseases (ILD). Particular emphasis will be on idiopathic pulmonary fibrosis (IPF), one of more than 130 types of ILD, which is characterized by scarring and/or inflammation of the interstitium the area surrounding the air sacs at the end of each airway in the lungs.

Both the Pulmonary Fibrosis Foundation and the National Institutes of Health have recognized National Jewish Health for its expertise in IPF and ILD. Our cuttingedge research and exceptional quality of care offers our patients access to the latest clinical trials and most effective treatments. To sign up for future Dialogue with a Doc discussions, please visit njhealth.org/DocSeries

Elizabeth F. Redente, PhD https://www.nationaljewish.org/doctor...

Jeffrey James Swigris, DO, MS

Interstitial Lung Disease (ILD)/Pulmonary Fibrosis
https://www.nationaljewish.org/condit...

Idiopathic Pulmonary Fibrosis (IPF)
https://www.nationaljewish.org/clinic...

Interstitial Lung Disease (ILD) Program
https://www.nationaljewish.org/direct...

COVID19 Information
https://www.nationaljewish.org/patien...